TRANSDERMAL NICOTINE TREATMENT OF MCI

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a three-site 12-month pilot clinical trial of the safety and efficacy of transdermal nicotine in alleviating symptoms of Mild Cognitive Impairment (MCI). The trial will consist of 6 months of randomized double-blind placebo-controlled treatment with nicotine or placebo followed by 6 months of open label nicotine treatment. The primary goal of this trial will be to establish the safety of long-term nicotine in non-smoking older patients with a secondary goal of examining whether nicotine will alleviate cognitive symptoms of MCI and whether this effect will be detectable by patients and clinicians. While this trial will not be sufficiently large enough or long enough to obtain data on the effects of nicotine on the progression of cognitive impairment to Alzheimer's disease, we hope that the results of this trial will justify a larger multi-center trial of sufficient duration to fully examine this question.